San Antonio Breast Cancer Symposium® 2021 
Lorem ipsum dolor sit amet

Join Us for a Webinar

Highlights of SABCS 2021

Join Dr. Christy Russell (VP, US Medical Affairs at Exact Sciences) as she reviews new data presented at SABCS 2021 and their implications for clinical management of breast cancer patients. Included will be an in-depth discussion of the latest data from the landmark RxPONDER trial. Dr. Russell will be available for a live Q&A following the presentation

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation  Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation 

Speakers

Anna Smith

CTO, US Medical Affairs
Precision Oncology

Christy Russell

Vice President, US Medical Affairs
Precision Oncology

Dates

Thursday,

3:00 PM PT / 6:00 PM ET

RxPONDER Clinical Trial Key Findings1

At SABCS 2020, Kevin Kalinsky, MD presented early RxPONDER data.

  • The majority of HR+, HER2-, N1 patients can be spared chemotherapy when decisions are guided with the Oncotype DX test
  • Postmenopausal women with 1-3 positive nodes and Recurrence Score result 0-25 can forgo adjuvant chemotherapy regardless of clinical pathological parameters
  • Premenopausal women with 1-3 positive nodes and Recurrence Score result 0-25 significantly benefit from chemotherapy

RxPONDER study results are expected to be practice-changing for N1 HR+, HER2-, early breast cancer patients